Core Viewpoint - The company reported significant revenue growth in the first half of 2025, but also posted a net loss for the period [1] Financial Performance - The company achieved operating revenue of 130 million yuan, representing a year-on-year increase of 61.8% [1] - The net profit attributable to shareholders was a loss of 162 million yuan [1] - The basic earnings per share were reported at -0.29 yuan [1] Revenue Sources - The primary revenue during the reporting period was generated from the sales of Pazopanib tablets (brand name: Dipeite) and Neralitinib tablets (brand name: Ouyoubi) [1]